Wednesday, November 11, 2026

MP Materials targets 10,000-tonne magnet output by 2028 to power AI hardware expansion

MP Materials plans to commission its 10X magnet facility in 2028, scaling annual production from 1,000 to 10,000 metric tonnes. The tenfold capacity increase aims to supply permanent magnets for electric motors in robotics and AI data center cooling systems as US manufacturers reduce China dependence.

MP Materials targets 10,000-tonne magnet output by 2028 to power AI hardware expansion
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

MP Materials expects its 10X magnet manufacturing facility to enter commissioning in 2028, expanding production capacity from 1,000 to 10,000 metric tonnes annually. The facility will produce neodymium-iron-boron (NdFeB) permanent magnets used in electric motors and actuators across AI hardware applications.

Permanent magnets power servo motors in industrial robots and collaborative robots deployed in AI-driven manufacturing. Data centers running AI workloads use magnet-based motors in cooling systems and backup generators. The 10X facility's output could supply magnets for approximately 1 million electric motors annually, based on typical automotive and industrial motor magnet content.

MP Materials operates the Mountain Pass rare earth mine in California, the only US source of rare earth elements. The company currently processes rare earth concentrate at Mountain Pass and ships material to China for magnet manufacturing. The 10X facility represents the final stage of domestic vertical integration, eliminating China from the supply chain.

China controls 90% of global permanent magnet production and 70% of rare earth mining. US automakers, defense contractors, and technology companies face supply chain risks from this concentration. The US Department of Defense designated rare earths as critical materials in 2021, citing national security concerns over China's market dominance.

The facility will use MP Materials' patented magnequench technology to produce magnets at scale. Initial capacity targets industrial and automotive customers before expanding to consumer electronics. The company has not disclosed capital costs for the 10X facility or magnet pricing.

Demand for permanent magnets is projected to grow 8-10% annually through 2030, driven by electric vehicle adoption and industrial automation. AI hardware infrastructure adds incremental demand as hyperscalers build data centers and robotics deployments accelerate in logistics and manufacturing sectors.

The 2028 timeline positions MP Materials to capture market share as US companies diversify supply chains away from Chinese suppliers. Competing US magnet projects from Vacuumschmelze and Urban Mining Company target smaller production scales with 2026-2027 start dates.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· January 13, 2026
    Will the US’ onshoring strategy remove China’s chokehold on REEs?
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com